RESUMO
In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization.
Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Infecções por Vírus Respiratório Sincicial , Antivirais/administração & dosagem , Displasia Broncopulmonar/epidemiologia , Feminino , Cardiopatias Congênitas/epidemiologia , Humanos , Programas de Imunização/métodos , Programas de Imunização/organização & administração , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Recém-Nascido de muito Baixo Peso , Masculino , Palivizumab , Avaliação de Programas e Projetos de Saúde/estatística & dados numéricos , Sistema de Registros , Infecções por Vírus Respiratório Sincicial/epidemiologia , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Fatores de Risco , Federação Russa/epidemiologiaRESUMO
A study was made of adaptation of the circulatory system in 40 full-term newborns with grade II and III intrauterine++ hypotrophy during the early neonatal period. Analysis of the hemodynamics demonstrated the study group children to have arterial hypertension, BP lability, and high peripheral vascular resistance. The conclusion has been made about the necessity of classifying intrauterine hypotrophy newborns with the group at risk for adaptation failure in the circulatory system.
